Articles

Vertex launches Journavx after FDA approval for acute pain

Vertex’s Journavx (suzetrigine) became the first FDA-approved non-opioid analgesic for moderate to severe acute pain on January 30, 2025. This plan frames the catalyst, label, and upcoming clinical milestones for BD teams, investors, and analysts.

AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint

AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.

Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis

Only about 5% of rare diseases have an FDA-approved drug, but gene therapies are gaining ground. This analysis covers the latest FDA approved gene therapy list, including the recent approval of Kresladi for LAD-I, and what it means for pharma teams and investors.

Amneal Romidepsin FDA Approval: B2B Analysis for BD Teams and Investors

Amneal Pharmaceuticals received FDA approval for its ready-to-use romidepsin injection solution, a competitive generic therapy for T-cell lymphomas. The 180-day CGT exclusivity positions Amneal for significant market capture, with implications for generic competition and brand dynamics.

Eli Lilly Retatrutide Phase 3: Safety Data and Competitive Implications

Eli Lilly presented new safety and tolerability data on retatrutide at the American Diabetes Association meeting. This article analyzes the Phase 3 results, competitive positioning, and key milestones for BD and investment teams.

Summit Pipeline Approvals and Competitive Outlook: 2023-2024 Update

Summit Carbon Solutions received Iowa regulatory approval for its CO2 pipeline in June 2024, marking a key milestone. This analysis covers the approval timeline, ongoing opposition, and what BD teams and investors should monitor next.

McGuireWoods' Alyssa Campbell Honored in M&A Advisor Emerging Leaders Awards

McGuireWoods partner Alyssa Campbell has been selected for The M&A Advisor's 2026 Emerging Leaders Awards, recognizing young professionals for success in M&A, turnarounds, and financing. Campbell's deep experience in private equity-backed M&A transactions signals continued strength in deal advisory for pharma and life sciences clients.

Lundbeck Advances Lu AG09222 After Phase 2 Migraine Data

Lundbeck is advancing its PACAP-targeting migraine drug Lu AG09222 into Phase 3 after Phase 2 data showed efficacy in patients not helped by prior treatments. The decision signals confidence in a novel mechanism that could compete with CGRP inhibitors.

Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond

Daraxonrasib nearly doubled overall survival in a Phase III trial for pancreatic ductal adenocarcinoma, an unprecedented outcome. This article analyzes the clinical data, regulatory implications, and strategic impact for pharma BD and investors.

Celcuity Expands VIKTORIA-2 Trial as Shares Trade Below Analyst Targets

Celcuity has expanded its Phase 3 VIKTORIA-2 trial to include endocrine-sensitive HR+/HER2- advanced breast cancer patients. Despite the expansion, shares trade roughly 43% below the consensus analyst price target, signaling a potential value gap for investors and strategic partners.

FDA Flavored Vape Ban: Youth Risk and Pharma Implications

The FDA's evolving stance on flavored vapes and pouches, including recent authorizations of fruit-flavored e-cigarettes, raises renewed youth addiction risks. This analysis provides pharma strategists with a grounded view of regulatory changes, competitive implications, and next milestones.

Opinion: I led the CDC response to the 2014 Ebola epidemic. The new outbreak needs massive

Former CDC Director Tom Frieden argues that the new Ebola outbreak demands a massive, immediate, and meticulous response. This article provides a structured analysis for pharma strategy and BD teams on the implications and required actions.

Listeria Outbreaks 2026: FDA and CDC Soft Cheese Recall Analysis for Pharma

The FDA and CDC are investigating a Listeria outbreak linked to soft cheese recalls from Clover Hill Dairy and RAW FARM, LLC. This analysis covers the regulatory timeline, affected products, and strategic implications for pharmaceutical business development and investment teams.

Amish Health Beliefs: Vaccines, Costs, and Pharma Strategy Insights

This article analyzes Amish health behaviors, including low vaccination rates and selective medical care use, and their implications for pharmaceutical strategy and public health engagement.

5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis

In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.

EU Draft Merger Guidelines: Capabilities Treatment Needs Revisiting

The European Commission's draft merger guidelines shift focus to "capabilities," assessing how firms compete and pivot to future markets. This article examines the implications for pharmaceutical mergers and acquisitions.

Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN

This week, the biotech sector saw a wave of regulatory and business development activity: PHG and KMDA won FDA approvals, FULC halted its pociredir program, RMD closed the Noctrix acquisition, and NVS posted positive data in IgAN. We break down what each event means for pharma teams and investors.

The FDA Amendments Act And Drug Safety: Twenty Years Later

The FDA Amendments Act of 2007 (FDAAA) expanded FDA's authority to monitor drugs post-approval, mandating a population-based surveillance system and new disclosure rules. Twenty years later, progress is clear but the overall safety impact remains hard to quantify, offering key lessons for pharma BD and investors.

May 2026 FDA Oncology Actions: 8 Approvals Reshape the Landscape

In May 2026, the FDA issued 8 oncology and hematology approvals, including durvalumab for high-risk non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and what to watch next in FDA oncology guidance.

FDA clears U.S. trial of MAIA lung cancer drug for third-line patients

The FDA has cleared MAIA Biotechnology to open U.S. enrollment in the expanded Phase 2 THIO-101 trial of ateganosine for third-line non-small cell lung cancer. This milestone, combined with Fast Track designation, positions MAIA for potential Accelerated Approval and shifts the competitive landscape in late-line NSCLC.